ID   MR42D
AC   CVCL_RW50
SY   ENZR 42D; 42DENZR
DR   cancercelllines; CVCL_RW50
DR   Wikidata; Q54906571
RX   PubMed=25428917;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; MDV-3100).
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0395 ! LNCaP
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 05-10-23; Version: 10
//
RX   PubMed=25428917; DOI=10.18632/oncotarget.2703;
RA   Bishop J.L., Sio A., Angeles A., Roberts M.E., Azad A.A., Chi K.N.,
RA   Zoubeidi A.;
RT   "PD-L1 is highly expressed in Enzalutamide resistant prostate
RT   cancer.";
RL   Oncotarget 6:234-242(2015).
//